Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 12-Month High at $1.62

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high during trading on Tuesday . The company traded as high as 1.62 and last traded at 1.60, with a volume of 1449231 shares changing hands. The stock had previously closed at 1.53.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Oppenheimer reissued an “outperform” rating and issued a $1.50 target price (up from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley increased their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th.

Perspective Therapeutics Stock Performance

The company has a market cap of $977.22 million, a PE ratio of -16.85 and a beta of 1.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insiders Place Their Bets

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In other Perspective Therapeutics news, insider Markus Puhlmann bought 280,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was purchased at an average cost of 0.50 per share, for a total transaction of 140,000.00. Following the completion of the acquisition, the insider now owns 1,375,425 shares of the company’s stock, valued at 687,712.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The disclosure for this purchase can be found here. Insiders have purchased a total of 60,758,439 shares of company stock worth $57,576,503 over the last 90 days. Corporate insiders own 5.72% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently modified their holdings of the business. Perkins Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at about $731,000. HighTower Advisors LLC bought a new position in Perspective Therapeutics in the 3rd quarter worth about $314,000. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $42,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.